Dual immunotherapy shows promising activity in high-risk early-stage HER2-negative breast cancer. A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical trial results from the ongoing I-SPY2 clinical trial platform.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given before surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to Phase II clinical trial results from the ongoing I-SPY2 clinical trial platform.
- Ponto de atenção: dual.
- Ponto de atenção: immunotherapy.
- Ponto de atenção: shows.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
Acompanhe a Recifes.net
Entre no Canal do WhatsApp da Recifes.net para receber noticias, bastidores e atualizacoes editoriais diretamente no WhatsApp.
